Decheng Capital Management Iii (Cayman), LLC Phathom Pharmaceuticals, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 850,000 shares of PHAT stock, worth $14.9 Million. This represents 4.88% of its overall portfolio holdings.
Number of Shares
850,000
Previous 850,000
-0.0%
Holding current value
$14.9 Million
Previous $12.2 Million
27.59%
% of portfolio
4.88%
Previous 6.45%
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$177 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$131 Million27.45% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$61.3 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$55.1 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$51.3 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $686M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...